Literature DB >> 12070020

Thrombin functions during tissue factor-induced blood coagulation.

Kathleen E Brummel1, Sara G Paradis, Saulius Butenas, Kenneth G Mann.   

Abstract

Tissue factor-induced blood coagulation was studied in 20 individuals, for varying periods of time during 54 months, in contact pathway-inhibited whole blood at 37 degrees C and evaluated in terms of the activation of various substrates. After quenching over time with inhibitors, the soluble phases were analyzed for thrombin-antithrombin III (TAT) complex formation, prothrombin fragments, platelet activation (osteonectin release), factor Va generation, fibrinopeptide (FP) A and FPB release, and factor XIII activation. TAT complex formation, for 35 experiments, showed an initiation phase (up to 4.6 +/- 0.6 minutes) in which thrombin was generated at an average rate of 0.93 +/- 0.3 nM/min catalyzed by about 1.3 pM prothrombinase yielding approximately 26 nM thrombin. During a subsequent propagation phase, thrombin was generated at a rate of 83.9 +/- 3.8 nM/min by about 120 pM prothrombinase, reaching ultimate levels of 851 +/- 53 nM. Clot time, determined subjectively, occurred at 4.7 +/- 0.2 minutes and correlated with the inception of the propagation phase. The thrombin concentrations associated with the transitions to rapid product formation are 510 +/- 180 pM for platelet activation (1.9 +/- 0.2 minutes), 840 +/- 280 pM for factor XIII activation and factor Va generation (2.2 +/- 0.6 minutes), 1.3 +/- 0.4 nM for FPA release (2.5 +/- 0.7 minutes), 1.7 +/- 0.5 nM for FPB release and prethrombin 2 (2.8 +/- 0.8 minutes), 7.0 +/- 2.2 nM for thrombin B chain (3.6 +/- 0.2 minutes), and 26 +/- 6.2 nM for the propagation phase of TAT formation (4.6 +/- 0.6 minutes). These results illustrate that the initial activation of thrombin substrates occurs during the initiation phase at less than 2 nM thrombin (0.2%). Most thrombin (96%) is formed well after clotting occurs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070020     DOI: 10.1182/blood.v100.1.148

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  93 in total

1.  Coagulation procofactor activation by factor XIa.

Authors:  M F Whelihan; T Orfeo; M T Gissel; K G Mann
Journal:  J Thromb Haemost       Date:  2010-05-04       Impact factor: 5.824

2.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

3.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

4.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

5.  Membrane binding events in the initiation and propagation phases of tissue factor-initiated zymogen activation under flow.

Authors:  Laura M Haynes; Yves C Dubief; Kenneth G Mann
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

6.  Taking the thrombin "fork".

Authors:  Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07       Impact factor: 8.311

7.  Is there value in kinetic modeling of thrombin generation? Yes.

Authors:  K G Mann
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

8.  Mathematical and biological models of blood coagulation.

Authors:  T Orfeo; K G Mann
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

Review 9.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

10.  The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Samuel S Edwin; Chia-Ling Nhan-Chang; Nandor Gabor Than; Chong Jai Kim; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.